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Abstract Oral administration of sodium tungstate is an
effective treatment for type 1 and 2 diabetes in animal
models; it does not incur significant side effects, and it may
constitute an alternative to insulin. However, the mecha-
nism by which tungstate exerts its observed metabolic
effects in vivo is still not completely understood. In this
work, serum-containing proteins which bind tungstate have
been characterized. Size exclusion chromatography (SEC)
coupled to inductively coupled plasma mass spectrometry
(ICP-MS) with a Phenomenex Bio-Sep-S 2000 column and
20 mM HEPES and 150 mM NaCl at pH 7.4 as the mobile
phase was chosen as the most appropriate methodology to
screen for tungsten–protein complexes. When human serum
was incubated with tungstate, three analytical peaks were
observed, one related to tungstate–albumin binding, one to
free tungstate, and one to an unknown protein binding
(MW higher than 300 kDa). Matrix-assisted laser desorp-
tion ionization time-of-flight (MALDI-TOF) mass spectro-
metric analysis of the tungsten-containing fractions collected
from SEC–ICP-MS chromatograms, after desalting and
preconcentration processes, confirmed the association of
tungstate with albumin and the other unknown protein.
Keywords Tungstate . Diabetes . LC–ICP-MS .
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Introduction
Several inorganic substitutes for insulin, such as vanadate,
selenate and lithium salts, have been described [1]. In
several animal models with type 1 and 2 diabetes, sodium
tungstate reduces and, in most cases, normalizes glycemia
when administered orally [2]. In addition, several reports
have also shown antidiabetic actions for the tungsten
derivates paratungstate and pertungstate [3, 4]. In contrast
to other transition metal derivatives, sodium tungstate has a
low toxicity profile in both short- and long-term treatments
[5, 6]. Long-term tungstate treatment reduces body weight
gain and the occurrence of various complications of
diabetes in rats, such as morphological changes in kidney
and ocular lens, and also reduces mortality but does not
cause any undesirable side effects [7]. Despite numerous
studies, the mechanism by which tungstate performs its
observed metabolic effects in vivo is still not completely
understood. Thus, more research is still required to clarify
the biochemical forms and physiological functions of this
element in humans.
Elemental speciation studies using hyphenated techniques
such as liquid chromatography coupled to inductively
coupled plasma mass spectrometry (LC–ICP-MS) can be a
valuable tool for obtaining information about the biomole-
cules that may be involved in the biochemistry of tungsten
and its transport and storage in body fluids and tissues [8, 9].
Several separation techniques, such as gel electro-
phoresis [10], size-exclusion (SEC) [11] or ion exchange
chromatography [12–14] have been proposed for the sepa-
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ration and determination of metal biocompounds. SEC with
on-line detection by ICP-MS appears to be the primary
technique that allows metals bound to macromolecular li-
gands in an unknown sample to be detected [15]. It is known
that SEC has the ability to separate biomolecules into ranges
of different molecular weights, and ion exchange in the
anion-exchange mode also offers an interesting alternative
for the separation of metal biocompounds [12, 13]. The use
of anion exchange fast protein liquid chromatography (AE-
FPLC) coupled with ICP-MS has provided satisfactory
results when studying protein binding to metals such as
aluminum, iron and vanadium [16, 17].
In the present study, we have chosen to use AE-FPLC and
SEC coupled to ICP-MS detection in order to study the
association of tungstate with proteins in human serum. Ad-
ditionally, matrix-assisted laser desorption ionization mass
spectrometry (MALDI-TOF-MS) will be used to characterize
the protein moieties associated with tungsten fractions present
in human serum.
Experimental
Instrumentation
For tungsten determination, a Quadupole ICP-MS Thermo
X-Series (Thermo Electron, Windsford, UK) equipped with
a Meinhard nebulizer, a Fassel torch and an Impact Bead
Quartz spray chamber cooled by a Peltier system was
employed. The ICP-MS operating conditions were: forward
power 1250 W, plasma gas 15 L min−1, auxiliary gas 0.73 L
min−1, nebulizer gas 0.85 L min−1, channels per AMU 10,
and integration time 0.6 ms. For total tungsten determina-
tion, sample introduction was performed in continuous
mode and single-ion monitoring of m/z 184 (W), 186 (W)
and 191 (Ir) was used to collect data. 100 μg L−1 of Ir was
used as the internal standard.
For the speciation studies, which involved chromatograph-
ic separations, a high-pressure quaternary gradient pump
(Jasco PU-2089, Tokyo, Japan) equipped with a 20 μL
sample injection valve (Rheodine, Rohnert Park, CA, USA)
was used as a sample delivery system. Separation of the
proteins associated with tungstate was performed by SEC
using a Phenomenex Bio-Sep-S 2000 (300 mm ×7.8 mm
analytical gel filtration column, Pharmacia Biotech, Uppsala,
Sweden) with a separation range of 1–300 kDa, and with a
strong AE-FPLC Mono-Q H/R 5/5 column (50 mm×5 mm
i.d., Pharmacia,, both running at a flow rate of 1 mL min−1.
The ICP-MS transient signal mode was set to chromatograph-
ic acquisition, monitoring m/z 184 (W), 66 (Zn) and 65 (Cu).
UV measurements were performed with a SpectroMoni-
tor 5000 photodiode array detector (LDC Analytical Thermo
Separation Products, Uxbridge, UK).
Molecular mass analyses of different proteins associated
with tungsten were performed by MALDI-TOF-MS on a
Voyager™ Biospectrometry™ Workstation (Applied Bio-
systems, Langen, Germany). The operating parameters
employed were: positive mode 25 kV, 2600 A laser intensity,
100 laser shots.
A 5404R centrifuge (Eppendorf, Hamburg, Germany)
was used.
Reagents and materials
All chemicals were of analytical grade quality at the very
least. Human protein standards [albumin (HSA), apo-
transferrin (apo-Tf), immunoglobulin G (IgG) and α2-
macroglobulin] were obtained from Sigma (St. Louis, MO,
USA). Stock solutions of tungstate (1000 mg L−1 as tung-
sten in 5% nitric acid/trace hydrofluoric acid; Merck,
Darmstadt, Germany) and Ir (1000 mg L−1 in 8% HCl,
Merck, Darmstadt, Germany) were diluted with 5% HNO3
to prepare standard solutions. The different mobile phases
were prepared with tris(hydroxymethyl)-aminomethane
(Fluka Chemie, Buchs, Switzerland), ammonium acetate
(Merck), acetic acid (Merck), hydrochloric acid (Merck),
NaCl and KCl (Panreac Quimica SA, Castellar del Vallès,
Barcelona, Spain), HEPES [4-(2-hydroxyethyl)piperazine-
1-(2-ethanesulfonic acid)] (Sigma-Aldrich, Bornem, Belgium)
and NaOH (Merck). Sinapinic acid (Fluka, Steinheim,
Germany), trifluoroacetic acid (Aldrich, Steinheim, Germany)
and acetonitrile (Merck) were used for MALDI-TOF analysis.
All solutions were prepared with deionized water (Milli-Q
Ultrapure water systems, Millipore, MA, USA). High-purity
nitric acid was obtained by distillation of the analytical grade
reagents (Merck).
Fresh human serum was obtained from a healthy volunteer,
and was stored at –18 °C and defrosted immediately prior to
use.
Procedure used for in vitro studies
Independent solutions of 5 g L−1 HSA, 0.5 g L−1 apo-Tf,
and 1 g L−1 IgG were incubated with 5 μg L−1 WO24
solution (as tungsten) (previously neutralized at pH 7.0) at
37 °C for 1, 24, 48 and 96 h in a saline solution containing
0.9% NaCl and 10 mM HEPES buffer (pH 7.4) in order to
mimic physiological conditions. Aliquots of the incubated
solutions were further analyzed by LC–ICP-MS.
Freshly sampled human blood was separated into serum
and blood cells by centrifugation at 6000×g for 20 min, the
supernatant being transferred to a second vial and centri-
fuged a second time following the same procedure. It
should be noted that no particular precaution was taken to
prevent contamination of this serum from external sources,
such as stainless steel needles. Aliquots of this serum were
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incubated with 5 μg L−1 WO24 at 37 °C for 1, 24, 48 and
96 h. All serum samples were diluted (1+1) with mobile
phase before injection into the chromatographic system. All
of the samples were filtered through a 0.22-μm Millex-
GV13 filter (Millipore) before injection onto the column of
the LC–ICP-MS system for tungsten detection. In parallel,
LC–UV was used for protein monitoring at 280 nm.
Two fractions of the eluted human serum sample with
high tungsten contents were collected from the SEC column
at 6.6 min and 5.6 min (maximum peaks of HAS–W and
unknown protein–W, respectively; 1 mL each) in polypro-
pylene containers. This procedure was repeated twice to
give a final volume of 2 mL of each fraction. These frac-
tions were desalted and preconcentrated in a centrifugal
filter device (using Centricon YM-30 cut-off filters from
Millipore) by centrifugation at 5000×g and 20 °C for 1 h.
The retentate was made up to 200 μL with ultrapure water.
These aliquots were mixed with a saturated sinapinic acid
solution in 0.1% (v/v) trifluoroacetic acid:acetonitrile for
molecular mass protein identification by MALDI-TOF.
Results and discussion
LC–ICP-MS method development
Most biological systems are sensitive to small changes in
pH, so the pH values of the mobile phases and the solutions
in the in vitro incubation experiments should be carefully
controlled during the experiment using a buffer solution.
However, the potential interaction of metal–protein com-
plexes with the stationary and mobile phases of the chro-
matographic system could result in the poor recovery of the
target analyte [14, 17]. It is important to choose mild
separation chromatographic methods to avoid artefacts in
the resulting chromatograms. As no study related to the
interaction of tungstate with serum proteins has been
reported in the literature as yet, the development of a
suitable chromatographic method for tungstate–protein
separation and identification is mandatory. Thus, the suit-
abilities of two chromatographic columns based on differ-
ent separation mechanisms in combination with several
mobile phases were evaluated. The combination of either a
Mono-Q H/R 5/5 (strong anion exchange FPLC column) or a
Phenomenex Bio-Sep-S 2000 (1–300 KDa, SEC gel filtra-
tion column) with different mobile phases was evaluated.
Most serum proteins are glycoproteins, 52% of which
are albumin [18]. Other minority proteins are transferrin,
immunoglobulin G and macroglobulins, which have been
reported to bind and transport metal ions in human serum.
As HSA and apo-Tf have been reported to interact with
iron, aluminum and vanadium [8, 16, 19] (among other
species), 5 g L−1 HSA was incubated with 10 μg L−1 tung-
state for 24 h under physiological conditions (corresponding
to the different chromatographic mobile phases tested), and
the incubated sample was injected into the LC–ICP-MS
system for tungstate–HAS detection. In parallel, a 10 μg L−1
tungstate solution was also injected onto each column to
control the elution time of both free tungsten and those
associated with HSA, and to evaluate the recovery of
tungsten from the column. The results obtained, shown in
Table 1, shown that tungsten (whether free or associated
with protein) is strongly retained in the Mono-Q column for
the different mobile phases tested. It is known that tungstate
forms isopolytungstates with a high anionic charge at
neutral pH. The presence of this highly charged species
indicates that this polyanion is strongly retained on the
anionic exchange column. However, the situation is signif-
icantly different for that reported for vanadium, which also
forms polyanions [14].
In contrast, when the Phenomenex Bio-Sep-S 2000 SEC
column was used, quantitative recovery was achieved only
when HEPES buffer was used as the mobile phase in
isocratic mode. Similar results for vanadium associated
with proteins have been reported by other authors, which
stated that HEPES, unlike to other buffers, does not interact
with vanadium in solution [14]. Furthermore, an additional
advantage of using a SEC column with HEPES as the
Table 1 Chromatographic conditions tested for the separation of tungstate complexes with human serum proteins
Column Mobile phase W–protein recovery Inorganic W recovery
Mono Q HR 5/5 (AE-FPLC) A: 50 mM tris-HAc, pH 7.4 No No
B: 50 mM tris-HAc/250 mM NH4Ac, pH 7.4
A: 50 mM tris-HCl, pH 7.4 No Yes
B: 50 mM tris-HCl/250 mM NH4Ac, pH 7.4
A: 20 mM HEPES, pH 7.4 No Yes
B: 20 mM HEPES/150 mM NaCl, pH 7.4
Phenomenex Bio-Sep-S 2000 (SEC) 25 mM Tris-HCl/50 mM KCl, pH 6.8 <30% Quantitative
20 mM HEPES/150 mM NaCl, pH 7.4 Quantitative Quantitative
Gradient elution conditions: A starting buffer, B terminal buffer
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mobile phase is that the chromatogram is obtained more
rapidly (14 min) than when obtained using the Mono-Q
column with other mobile phases (30 min). This fact is
especially relevant to mobile phases with a high saline
content because it provides a drastic decrease in signal drift
when ICP-MS is used as the detector. Thus the SEC column
with 20 mM HEPES and 50 mM NaCl at pH 7.4 as mobile
phase was selected for further study. We checked that this
chromatographic system could work contamination-free,
despite of its stainless steel components.
Tungstate–protein binding kinetics
The interactions of tungstate with human serum proteins
were evaluated by incubating individual standards of 5 g
L−1 HSA, 0.5 g L−1 apo-Tf and 1 g L−1 IgG with this
metallic species (5 μg L−1 of tungsten). The different
mixtures (tungstate–protein) were incubated at 37 °C for 2,
24, 48 and 96 h in saline solution (5 mM HEPES and
150 mM NaCl at pH 7.4).
The ICP-MS chromatographic profiles of W-complexes
with different proteins after 2 h of incubation are shown in
Fig. 1. In addition, the proteins were also spectrophotomet-
rically detected at 280 nm. Good chromatographic resolu-
tion between free tungstate and both W-proteins was
obtained, with the inorganic tungstate being the last species
eluted in the chromatogram (9.5 min). All tungsten species
eluted in 11 min with relatively symmetrical peaks and
show no significant tailing. However, tungstate bound to
HSA and apo-Tf coelute at a retention time of 6.5 min.
As can be observed in Fig. 1 and Table 2, tungstate
forms complexes with HSA and apo-Tf, but not with IgG.
About 40% and 10% of the tungstate interacts with HSA
and apo-Tf, respectively, for an incubation time of 2 h.
Prolonging the incubation time did not increase the com-
plexation, which indicates that a fast kinetic process occurs
for this kind of binding, which is far from being
quantitative. It has been already reported that the presence
of hydrogen carbonate anion seems to be required for
adequate binding of V, Fe and Al ions to apo-Tf [19]. Thus,
parallel incubation experiments with HSA or apo-Tf and
tungstate in 0.025 M sodium hydrogen carbonate were
carried out; however, no W–protein complex was observed
in this medium.
Since the serum concentration of HSA is considerably
greater than that of Tf, most tungstate in serum should be
bound to HSA instead of Tf.
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Fig. 1 SEC–ICP-MS (dashed line) and UV–HPLC (dotted line)
chromatograms of standard solutions of human serum proteins incubated
with 5 μg L−1 tungsten and : (a) 5 mg L−1 HSA; (b) 0.5 mg L−1 apo-Tf;
(c) 1 mg L−1 IgG; and (d) human serum
b
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Binding of tungstate to human serum proteins
The total content of tungsten in human serum samples from
a healthy subject was lower than the detection limit of the
ICP-MS (5 ng L−1). The serum samples were incubated at
37 °C with 5 μg L−1 of tungstate for 2, 24, 48 and 96 h.
Three analytical peaks corresponding to the presence of
different species (free and bound) of tungsten were detected
(Fig. 1d) after 2 h of incubation time. The chromatographic
peaks at 6.6 min (F2) and 9.5 min match those previously
obtained for tungstate complexed to HSA and/or apo-Tf
and free tungstate, respectively. However, the analytical
peak eluted at 5.6 min does not match any of the previously
characterized tungsten compounds, and corresponds to the
exclusion volume of the column. Therefore the MW of this
W–protein should be higher than 300 kDa. It is important to
note that, as seen for the protein standards, incubating for of
>2 h did not result in any significant improvement in the
extent of protein binding.
Considering that the interaction of α2-macroglobulin
with zinc and molybdenum in serum samples has already
been reported [20], and that in some proteins molybdenum
can be replaced by tungsten [20], the possibility that the
unknown tungsten species detected at 5.6 min (F1) could
correspond to a tungstate complex with α2-macroglobulin
was evaluated. Thus, a solution of 1.5 g L−1 α2-macroglobulin
was incubated with 5 μg L−1 of tungstate at 37 °C for 2 and
24 h, but no interaction was observed.
In order to check the effect of the tungstate concentration
on the protein binding efficiency, three different concen-
trations of tungstate (5, 10 and 50 μg L−1) were spiked into
the human serum which was then incubated for 2 h. The
results obtained (Table 2) show that the percentage of free
inorganic tungsten remains almost constant in all cases,
independent of the initial tungsten concentration used.
In order to test the reproducibility of the developed
method, three human serum samples were incubated with
5 μg L−1 of tungstate for 2 and 24 h. The analysis of each
incubated serum was performed in duplicate and the RSD
for each identified tungsten species was in the range 2–7%.
A comparison of the means using the Snedecor test did not
indicate that there was any significant difference between
both incubation series for α (0.05, n=3).
Taking advantage of the multielemental capabilities of
ICP-MS, the chromatographic profiles of other essential
elements (such as zinc and copper) associated with human
Table 2 Binding efficiency of
5 μg L−1 tungstate (W) to
different serum proteins after
2 h of incubation
Values given are the extent of
tungstate–protein binding (%)
after tungstate is spiked into
human serum.
WO24
 
;2gL1 Matrix Unknown–W Ig–W Apo–W HSA–W Winorganic
5 HAS – – – 40 60
5 Apo-tf – – 11 – 89
5 IgG – – – – 100
5 Serum 20 – – 45 35
10 Serum 22 – – 47 31
50 Serum 19 – – 42 39
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Fig. 2 MALDI-TOF spectrums
observed for fractions F1 and F2
collected from SEC–ICP-MS,
corresponding to (a) a human
serum sample F1A, F2A and
(b) a human serum sample
incubated with 10 μg L−1
tungstate F1B, F2B
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serum proteins were monitored. The fact that similar
chromatographic profiles were obtained for zinc, copper
and tungsten (Fig. 1) could lead us to assume that tungstate is
associated with the same proteins as these other two essential
elements. The main difference found was the presence of
both free and bound tungstate to proteins, which was not
observed for the other essential elements.
Identification of proteins bound to tungstate
by MALDI-TOF
Unaltered protein analysis is one of the capabilities of the
MALDI-TOF technique. Since most proteins obtain charges
of +1 and/or +2 in this source, the resulting mass spectra
are much easier to interpret than those obtained using an
electrospray ionization (ESI)-MS. Furthermore, the sample
treatment required for MALDI-TOF is simpler than that
required for ESI-MS, where samples need to be free of
significant salt content. Thus, the molecular weights of
proteins can easily be calculated directly from the MALDI-
TOF mass spectra. In order to check whether the two main
peaks observed in the SEC–ICP-MS chromatograms could
be related to differences in molecular weight, the two
fractions (F1 and F2 in Fig. 1) were collected, desalted,
preconcentrated ten times using Centricon YM-30 centrif-
ugal filters, and finally analyzed by MALDI-TOF.
Mass values were calculated as the means and standard
deviations of nine different sample spots. All mass spectra
were recorded and averaged over 100 laser shots. Figure 2
shows the MALDI-TOF mass spectra obtained for fractions
F1 and F2, corresponding to an unspiked human serum
sample (A) and human serum spiked with 10 μg L−1 tung-
state (B). External calibration of the instrument was
achieved by placing several aliquots of a standard solution
of HSA (MW 66,554) in alternative holes of the MALDI
plate.
To confirm that fraction F2 contained tungstate associ-
ated with HSA, the spectra of sera with and without
tungstate were compared. However, it should be noted that
albumin gives a wide peak in MALDI-TOF, which limits
the accuracy of the molecular mass obtained. The molecular
ion (M+H)+ for the unspiked serum (F2A) was observed at
m/z 66,566±25 Da (Fig. 2, F2A) very close to the theo-
retical value for HSA (66,554 Da). No peaks were obtained
for apo-Tf (76,000 Da) in this fraction. The mass difference
between the peaks in the spectra for fraction F2 serum
samples with (F2B) and without (F2A) tungstate incubation
was 214 Da, which can be attributed to tungstate binding
(248 Da). The fact that the protein–tungstate binding was
detected by MALDI-TOF contrasts with the data reported
for vanadium–transferrin binding [19], where the integrity
of the vanadium–protein binding was not maintained during
the MALDI process. In our case we can assume that HSA is
one of the proteins responsible for binding to tungstate.
Parallel experiments with fraction F1 gave a molecular
ion (M+H)+ for the unspiked serum (Fig. 2, F1A) at m/z
66,645±62 Da, very close to the theoretical of HSA. These
results can be attributed to either the contamination of this
fraction with HSA (it should be noted that the F1 and F2
chromatographic peaks are not completely resolved), or to
the presence of a protein with a molecular weight similar to
that of HSA. Furthermore, a molecular mass increase of
252 Da was observed when tungstate was present in the
incubation (F1B), which again confirms that the tungstate
binds to this protein.
Conclusions
An analytical screening method which allows the binding
of tungstate to serum proteins to be identified has been de-
veloped for the first time. The chromatographic method—
which is based on the use of SEC–ICP-MS coupling—lasts
15 min, which is much shorter than the time required for
other antidiabetic target compounds.
MALDI-TOF analysis of SEC tungsten-containing frac-
tions confirmed that albumin complexes tungstate. The
presence of other unknown W–protein peaks shows that
more research in this area is required using an alternative
analytical methodology.
An important feature of the binding of the tungstate to
serum proteins is the fact that, in all cases, and independent
of the tungstate concentration used, the presence of free
tungstate was detected.
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